Wisp, the largest women’s telehealth platform in the U.S., launches at-home STI testing and GLP-1-based weight care—advancing its virtual women’s health platform across all 50 states.
Wisp’s At-Home STI Testing: A New Era for Women’s Health
As clinic access shrinks and provider shortages rise, Wisp—the largest pure-play women’s telehealth platform in the U.S., available in all 50 states—is betting big on home as the new front line of healthcare. Today, the company launched a diagnostics vertical designed to bring testing and follow-up care for common STIs directly to patients’ doors.
With more than 1.5 million users nationwide, Wisp has quietly become a category-defining force in virtual women’s health. Its new At-Home Testing & Follow-Up Care service allows patients to collect samples discreetly at home, mail them to CLIA/CAP-accredited labs, and receive results within 3–5 business days—no clinic visit required. All tests include free consultations and, if needed, asynchronous treatment within the Wisp platform.
“We’re simplifying the path to complete, 360-degree care, making it possible for patients to access testing and treatment from the comfort of home,” said Monica Cepak, CEO of Wisp.
Inside Wisp’s Diagnostic Panels: STI Testing Without the Clinic
Wisp’s diagnostics offering debuts with three test panels: a Common STI Panel (Chlamydia, Gonorrhea, and Trichomoniasis), a 3-Site Panel (multi-site Chlamydia and Gonorrhea), and an M-Gen Panel (Mycoplasma Genitalium). All tests are processed through CLIA/CAP-accredited labs using non-invasive swab and urine samples.
According to Wisp, 62% of surveyed patients expressed interest in at-home STI testing. The platform’s STI, STD, and Herpes categories are up 40% year-over-year.
“We’re not just improving convenience—we’re helping to destigmatize sexual health and empower patients to take control of their care with confidence,” said Dr. Jillian LoPiano, MD, MPH, FACOG.
Strategic Partnerships Power Wisp’s Holistic Care Model
Wisp is actively building an interconnected care ecosystem through strategic partnerships:
- With Daye, it launched a CLIA-validated vaginal microbiome screen using diagnostic tampons for BV, yeast, and fertility insights.
- With Origin, Wisp provides pelvic floor physical therapy for menopause, postpartum, and sexual wellness.
- And with Nourish, it now offers one-on-one nutrition counseling for patients on GLP-1 medications like Ozempic and Wegovy.
“These partnerships reflect our commitment to holistic, inclusive care—delivered with flexibility and privacy,” said Cepak.
Wisp’s GLP-1 Weight Care Program Tackles Hormonal Health
In March 2025, Wisp launched a comprehensive weight care vertical that includes access to GLP-1 medications for women navigating hormonal imbalances, PCOS, and perimenopause. The offering consists of prescription access, metabolic panels, and support tools to monitor nutritional deficiencies and long-term weight maintenance.
The move positioned Wisp as one of the few platforms approaching GLP-1s from a women’s hormonal health lens, not just weight loss.
“There’s a gap in the GLP-1 conversation around how hormones impact outcomes,” said Cepak. “We wanted to create a pathway that considers the full picture.”
Addressing Recurrence: Wisp’s Male BV Partner Prescription
Wisp also recently launched a first-of-its-kind Male BV Partner Treatment, addressing a longstanding clinical blind spot. The new product provides prescriptions for male partners to prevent reinfection and reduce recurrence rates of BV in female patients.
“This move is about science, empathy, and eliminating recurring frustration for our patients,” said Dr. LoPiano.
Organic Growth and Profitability: How Wisp Scaled Without VC
In a recent interview with Femtech Insider, Cepak shared how Wisp’s lean growth strategy was fueled by SEO and trust, not splashy fundraising. Over 60% of new patients find Wisp through organic search, and the company has remained profitable since before its 2021 acquisition by WELL Health Technologies (Forbes).
“We focused on listening to our customers and solving real problems, faster and more affordably than anyone else,” said Cepak.
Who Else Is Building the Future of Women’s Health?
Wisp is one of the only DTC platforms offering a fully virtual stack—from diagnostics and treatment to Rx delivery and hormonal health—available in all 50 states.
As Wisp pushes beyond birth control into diagnostics, weight care, and asynchronous treatment, its competitive set reveals a fragmented market—one where most players specialize in narrow verticals, not comprehensive care.
Here’s how the landscape stacks up:
- Nurx (Thirty Madison): Known for birth control and STI testing with asynchronous care. Recently merged into Thirty Madison. Doesn’t offer GLP-1 support or holistic hormonal care.
- Hey Jane: A leader in virtual medication abortion with strong care coordination, but limited scope beyond reproductive health.
- Cleo: A B2B women’s health platform focused on fertility and parenting support. Doesn’t offer DTC diagnostics or prescriptions.
- Maven Clinic: The most comprehensive virtual women’s health platform at the enterprise level, covering everything from fertility to menopause. However, it doesn’t offer direct-to-consumer diagnostics, and medication fulfillment is not core to the platform.
- Tia: A hybrid clinic-telehealth model offering integrative care. Diagnostic services are only available in-person. Tia recently scaled back its clinic expansion plans.
Reproductive Health Branding in a Post-Roe World
Wisp is among a new wave of digital health companies redefining reproductive health branding. In the wake of Roe v. Wade’s overturning, the company has embraced direct, unapologetic messaging around sexual health and bodily autonomy.
As reported by The Guardian, Wisp deliberately avoids euphemisms and medical gatekeeping in favor of plainspoken, rights-based language. This strategy is on full display in its award-winning campaign, “We Heart Healthy Vaginas.”
Created by agency Oberland, the Valentine’s Day-themed campaign used playful packaging, reclaimed language, and merch like “pH-balanced” candy hearts to promote awareness of Wisp’s vaginal health offerings. The campaign reached over 30 million impressions and boosted first-time patients.
“We don’t want our users to feel like they’re entering a hospital portal. We want them to feel seen,” said Cepak. “Our brand is a promise—not just a product.”
WELL Health’s Acquisition: Wisp’s Path to Profit and Scale
Founded in 2018 by Matthew Swartz, Wisp scaled without raising traditional VC capital. In 2021, it was acquired by WELL Health Technologies, a Canadian public company focused on digital health platforms.
Though WELL is based in Canada, Wisp serves patients exclusively in the U.S. across all 50 states, with over 1.5 million users and growing.
“Wisp’s expansion into diagnostics is a move that reflects our shared vision of building a fully integrated, patient-first healthcare experience. By bringing lab-grade testing into the home and pairing it with accessible virtual care, Wisp is not only enhancing convenience and affordability, but it’s redefining what 360-degree care looks like for women.” — Hamed Shahbazi, Founder, Chairman and CEO of WELL Health Technologies
“This launch underscores our founding mission: to put more power, privacy, and choice in the hands of patients,” said Cepak.
Toward a Seamless Digital Front Door for Women’s Health
As telehealth evolves from transactional visits to full-stack care, Wisp is laying the foundation for an always-on, lifestyle-centric women’s health platform. Diagnostics is just the latest step.
From birth control and STI testing to fertility, weight care, and hormonal health, Wisp is building what may become the most complete digital front door for women’s health.
Read more on how GLP-1 telehealth models are evolving in this Forbes feature.